Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR

PLoS ONE

Volumn 5, Issue 2, 2010, Pages

  Dere, Ruhee ^a   Wilson, Patricia D ^b   Sandford, Richard N ^c   Walker, Cheryl Lyn ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b MEDICAL COLLEGE OF WISCONSIN   (United States)

^c UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; PHOSPHATIDYLINOSITOL KINASE; POLYCYSTIN 1; PROTEIN KINASE B; TUBERIN; MAMMALIAN TARGET OF RAPAMYCIN; POLYCYSTIC KIDNEY DISEASE 1 PROTEIN; POLYCYSTIN; PROTEIN 14 3 3; PROTEIN SERINE THREONINE KINASE; SERINE; SIGNAL PEPTIDE; TUMOR SUPPRESSOR PROTEIN;

AMINO TERMINAL SEQUENCE; ARTICLE; CELL MEMBRANE; CELLULAR DISTRIBUTION; EUKARYOTIC FLAGELLUM; HUMAN; HUMAN CELL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE; ADULT; CELL LINE; CHEMISTRY; GENETICS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; KIDNEY POLYCYSTIC DISEASE; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY; RNA INTERFERENCE;

ANIMALIA; PYRONIA TITHONUS;

14-3-3 PROTEINS; ADULT; CELL LINE; HUMANS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MIDDLE AGED; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROTEIN BINDING; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RNA INTERFERENCE; SERINE; SIGNAL TRANSDUCTION; TRPP CATION CHANNELS; TUMOR SUPPRESSOR PROTEINS;

EID: 77949528561     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0009239     Document Type: Article

References (56)

1. Wilson PD (2004) Polycystic kidney disease: new understanding in the pathogenesis. Int J Biochem Cell Biol 36: 1868-1873.
2. Chang MY, Ong AC (2008) Autosomal dominant polycystic kidney disease: recent advances in pathogenesis and treatment. Nephron Physiol 108: 1-7.
3. Igarashi P, Somlo S (2002) Genetics and pathogenesis of polycystic kidney disease. J Am Soc Nephrol 13: 2384-2398.
4. Wilson PD, Goilav B (2007) Cystic disease of the kidney. Annu Rev Pathol 2: 341-368.
5. Torres VE, Harris PC, Pirson Y (2007) Autosomal dominant polycystic kidney disease. Lancet 369: 1287-1301.
6. Consortium IPKD (1995) Polycystic kidney disease: the complete structure of the PKD1 gene and its protein. Cell 81: 289-298.
7. Mochizuki T, Wu G, Hayashi T, Xenophontos SL, Veldhuisen B, et al. (1996) PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein. Science 272: 1339-1342.
8. Peters DJ, Spruit L, Saris JJ, Ravine D, Sandkuijl LA, et al. (1993) Chromosome 4 localization of a second gene for autosomal dominant polycystic kidney disease. Nat Genet 5: 359-362.
9. Nims N, Vassmer D, Maser RL (2003) Transmembrane domain analysis of polycystin-1, the product of the polycystic kidney disease-1 (PKD1) gene: evidence for 11 membrane-spanning domains. Biochemistry 42: 13035-13048.
10. Sutters M (2006) The pathogenesis of autosomal dominant polycystic kidney disease. Nephron Exp Nephrol 103: 149-155.
11. Sutters M, Germino GG (2003) Autosomal dominant polycystic kidney disease: molecular genetics and pathophysiology. J Lab Clin Med 141: 91-101.
12. Weston BS, Malhas AN, Price RG (2003) Structure-function relationships of the extracellular domain of the autosomal dominant polycystic kidney disease-associated protein, polycystin-1. FEBS Lett 538: 8-13.
13. Hanaoka K, Qian F, Boletta A, Bhunia AK, Piontek K, et al. (2000) Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents. Nature 408: 990-994.
14. Ibraghimov-Beskrovnaya O, Bukanov NO, Donohue LC, Dackowski WR, Klinger KW, et al. (2000) Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1. Hum Mol Genet 9: 1641-1649.
15. Streets AJ, Newby LJ, O'Hare MJ, Bukanov NO, Ibraghimov-Beskrovnaya O, et al. (2003) Functional analysis of PKD1 transgenic lines reveals a direct role for polycystin-1 in mediating cell-cell adhesion. J Am Soc Nephrol 14: 1804-1815.
16. Wilson PD, Geng L, Li X, Burrow CR (1999) The PKD1 gene product, "polycystin-1," is a tyrosine-phosphorylated protein that colocalizes with alpha2beta1-integrin in focal clusters in adherent renal epithelia. Lab Investig 79: 1311-1323.
17. Wilson PD (2008) Chapter 6 mouse models of polycystic kidney disease. Curr Top Dev Biol 84: 311-350.
18. Kim E, Arnould T, Sellin LK, Benzing T, Fan MJ, et al. (1999) The polycystic kidney disease 1 gene product modulates Wnt signaling. J Biol Chem 274: 4947-4953.
19. Le NH, van der Bent P, Huls G, van de Wetering M, Loghman-Adham M, et al. (2004) Aberrant polycystin-1 expression results in modification of activator protein-1 activity, whereas Wnt signaling remains unaffected. J Biol Chem 279: 27472-27481.
20. Le NH, van der Wal A, van der Bent P, Lantinga-van Leeuwen IS, Breuning MH, et al. (2005) Increased activity of activator protein-1 transcription factor components ATF2, c-Jun, and c-Fos in human and mouse autosomal dominant polycystic kidney disease. J Am Soc Nephrol 16: 2724-2731.
21. Low SH, Vasanth S, Larson CH, Mukherjee S, Sharma N, et al. (2006) Polycystin-1, STAT6, and P100 function in a pathway that transduces ciliary mechanosensation and is activated in polycystic kidney disease. Dev Cell 10: 57-69.
22. Shillingford JM, Murcia NS, Larson CH, Low SH, Hedgepeth R, et al. (2006) The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease. Proc Natl Acad Sci U S A 103: 5466-5471.
23. Kleymenova E, Ibraghimov-Beskrovnaya O, Kugoh H, Everitt J, Xu H, et al. (2001) Tuberin-dependent membrane localization of polycystin-1: a functional link between polycystic kidney disease and the TSC2 tumor suppressor gene. Mol Cell 7: 823-832.
24. Distefano G, Boca M, Rowe I, Wodarczyk C, Ma L, et al. (2009) Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1. Mol Cell Biol 29: 2359-2371.
25. Huang J, Manning BD (2008) The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. Biochem J 412: 179-190.
26. Inoki K, Guan KL (2009) Tuberous sclerosis complex, implication from a rare genetic disease to common cancer treatment. Hum Mol Genet 18: 94-100.
27. Gomez MR (1991) Phenotypes of the tuberous sclerosis complex with a revision of diagnostic criteria. Ann N Y Acad Sci 615: 1-7.
28. Kwiatkowski DJ, Manning BD (2005) Tuberous sclerosis: a GAP at the crossroads of multiple signaling pathways. Hum Mol Genet 14: 251-258.
29. Fingar DC, Richardson CJ, Tee AR, Cheatham L, Tsou C, et al. (2004) mTOR controls cell cycle progression through its cell growth effectors S6K1 and 4EBP1/ eukaryotic translation initiation factor 4E. Mol Cell Biol 24: 200-216.
30. Hay N, Sonenberg N (2004) Upstream and downstream of mTOR. Genes Dev 18: 1926-1945.
31. Wullschleger S, Loewith R, Hall MN (2006) TOR signaling in growth and metabolism. Cell 124: 471-484.
32. Bonnet CS, Aldred M, von Ruhland C, Harris R, Sandford R, et al. (2009) Defects in cell polarity underlie TSC and ADPKD-associated cystogenesis. Hum Mol Genet 18: 2166-2176.
33. Hartman TR, Liu D, Zilfou JT, Robb V, Morrison T, et al. (2009) The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycinin-sensitive and polycystin 1-independent pathway. Hum Mol Genet 18: 151-163.
34. Tao Y, Kim J, Schrier RW, Edelstein CL (2005) Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease. J Am Soc Nephrol 16: 46-51.
35. Wahl PR, Serra AL, Le Hir M, Molle KD, Hall MN, et al. (2006) Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD). Nephrol Dial Transplant 21: 598-604.
36. Wu M, Wahl PR, Le Hir M, Wackerle-Men Y, Wuthrich RP, et al. (2007) Everolimus retards cyst growth and preserves kidney function in a rodent model for polycystic kidney disease. Kidney Blood Press Res 30: 253-259.
37. Brook-Carter PT, Peral B, Ward CJ, Thompson P, Hughes J, et al. (1994) Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease-a contiguous gene syndrome. Nat Genet 8: 328-332.
38. Cai SL, Tee AR, Short JD, Bergeron JM, Kim J, et al. (2006) Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning. J Cell Biol 173: 279-289.
39. Arnould T, Kim E, Tsiokas L, Jochimsen F, Gruning W, et al. (1998) The polycystic kidney disease 1 gene product mediates protein kinase C alpha-dependent and c-Jun N-terminal kinase-dependent activation of the transcription factor AP-1. J Biol Chem 273: 6013-6018.
40. Hooper KM, Unwin RJ, Sutters M (2003) The isolated C-terminus of polycystin-1 promotes increased ATP-stimulated chloride secretion in a collecting duct cell line. Clin Sci (Lond) 104: 217-221.
41. Lal M, Song X, Pluznick JL, Di Giovanni V, Merrick DM, et al. (2008) Polycystin-1 C-terminal tail associates with beta-catenin and inhibits canonical Wnt signaling. Hum Mol Genet 17: 3105-3117.
42. Parnell SC, Magenheimer BS, Maser RL, Zien CA, Frischauf AM, et al. (2002) Polycystin-1 activation of c-Jun N-terminal kinase and AP-1 is mediated by heterotrimeric G proteins. J Biol Chem 277: 19566-19572.
43. Alexander A, Cai S, Kim J, Nanez A, Sahin M, et al. (2010) ATM Signals to TSC2 in the Cytoplasm to Regulate mTORC1 in Response to ROS. in press.
44. Benvenuto G, Li S, Brown SJ, Braverman R, Vass WC, et al. (2000) The tuberous sclerosis-1 (TSC1) gene product hamartin suppresses cell growth and augments the expression of the TSC2 product tuberin by inhibiting its ubiquitination. Oncogene 19: 6306-6316.
45. Deane JA, Ricardo SD (2007) Polycystic kidney disease and the renal cilium. Nephrology (Carlton) 12: 559-564.
46. Yoder BK (2007) Role of primary cilia in the pathogenesis of polycystic kidney disease. J Am Soc Nephrol 18: 1381-1388.
47. Fischer DC, Jacoby U, Pape L, Ward CJ, Kuwertz-Broeking E, et al. (2009) Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD). Nephrol Dial Transplant 24: 1819-1827.
48. Guay-Woodford LM (2003) Murine models of polycystic kidney disease: molecular and therapeutic insights. Am J Physiol Renal Physiol 285: F1034-1049.
49. Serra AL, Kistler AD, Poster D, Struker M, Wuthrich RP, et al. (2007) Clinical proof-of-concept trial to assess the therapeutic effect of sirolimus in patients with autosomal dominant polycystic kidney disease: SUISSE ADPKD study. BMC Nephrol 8: 13.
50. Braun WE (2009) Autosomal dominant polycystic kidney disease: emerging concepts of pathogenesis and new treatments. Cleve Clin J Med 76: 97-104.
51. Meijer E, de Jong PE, Peters DJ, Gansevoort RT (2008) Better understanding of ADPKD results in potential new treatment options: ready for the cure? J Nephrol 21: 133-138.
52. O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, et al. (2006) mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500-1508.
53. Pollizzi K, Malinowska-Kolodziej I, Stumm M, Lane H, Kwiatkowski D (2009) Equivalent benefit of mTORC1 blockade and combined PI3K-mTOR blockade in a mouse model of tuberous sclerosis. Mol Cancer 8: 38.
54. Sarbassov DD, Ali SM, Sengupta S, Sheen JH, Hsu PP, et al. (2006) Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB. Mol Cell 22: 159-168.
55. Zhang H, Cicchetti G, Onda H, Koon HB, Asrican K, et al. (2003) Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J Clin Invest 112: 1223-1233.
56. Neame SJ, Isacke CM (1992) Phosphorylation of CD44 in vivo requires both Ser323 and Ser325, but does not regulate membrane localization or cytoskeletal interaction in epithelial cells. Embo J 11: 4733-4738.